156 results on '"Derache, Nathalie"'
Search Results
2. Neurologic manifestations associated with COVID-19: a multicentre registry
- Author
-
Abgrall, Sophie, Alby-Laurent, Fanny, Allou, Thibault, Amevigbe, Joséphine, Amarguellay, Hanifa, Alloussi, Nabil, Baille, Guillaume, Barbaz, Mathilde, Bekri, Imen, Bencherif, Lamia, Bensaadi, Samia, Beraud, Guillaume, Bizot, Alexandra, Bottin, Laure, Bruneel, Fabrice, Camdessanche, Jean-Philippe, Chauffier, Jeanne, Csajaghy, Jean-Philippe, De Broucker, Chloé, De Broucker, Thomas, Defebvre, Luc, Delorme, Cécile, Dembloque, Elodie, Derache, Nathalie, Dereeper, Olivier, Derollez, Céline, Descotes-Genon, Cécile, Desestret, Virginie, Devaux, Mathilde, Dubuc, Lydie, Edan, Gilles, Fickl, Andréa, Fraisse, Thibault, Gugenheim, Michel, Hankiewicz, Karolina, Hansmann, Yves, Hautecloque-Raysz, Geoffroy, Henry, Carole, Jobard, Stéphanie, Jouan, Fanny, Kwiatkowski, Arnaud, Lalu, Thibault, Landre, Sophie, Lannuzel, Annie, Leguilloux, Johan, Lejeune, Camille, Liegeois, Clémence, Mahy, Sophie, Marey, Jonathan, Maury, Alexandra, Meppiel, Elodie, Michel, Laure, Mitri, Rita, Moulin, Chloé, Moulin, Solène, Peiffer-Smadja, Nathan, Omarjee, Asma, Ozsancak, Canan, Perrin, Peggy, Petitgas, Paul, Pico, Fernando, Poupard, Marie, Rabier, Valérie, Rizzato, Camille, Roos, Caroline, Saison, Julien, Sayre, Naomi, Sedillot, Nicolas, Sellal, François, Servan, Jérôme, Storey, Caroline, Suchet, Laurent, Tarteret, Paul, Tattevin, Pierre, Thiebaut, Mathilde, Vaduva, Claudia, Varlan, David, Wang, Adrien, Zarrouk, Virginie, Gorza, Lucas, SellaI, François, and de Broucker, Thomas
- Published
- 2021
- Full Text
- View/download PDF
3. Relapses During High-Dose Biotin Treatment in Progressive Multiple Sclerosis: a Case-Crossover and Propensity Score-Adjusted Prospective Cohort
- Author
-
Branger, Pierre, Parienti, Jean-Jacques, Derache, Nathalie, Kassis, Nizam, Assouad, Rana, Maillart, Elisabeth, and Defer, Gilles
- Published
- 2020
- Full Text
- View/download PDF
4. Impact of COVID-19 vaccination or infection on disease activity in a radiologically isolated syndrome cohort: The VaxiRIS study
- Author
-
Cohen, Mikael, primary, Thomel-Rocchi, Océane, additional, Siva, Aksel, additional, Okuda, Darin T, additional, Karabudak, Rana, additional, Efendi, Hüsnü, additional, Terzi, Murat, additional, Carra-Dalliere, Clarisse, additional, Durand-Dubief, Francoise, additional, Thouvenot, Eric, additional, Ciron, Jonathan, additional, Zephir, Helene, additional, Bourre, Bertrand, additional, Casez, Olivier, additional, De Seze, Jérôme, additional, Moreau, Thibault, additional, Neau, Jean-Philippe, additional, Pelletier, Daniel, additional, Kantarci, Orhun, additional, Tutuncu, Melih, additional, Derache, Nathalie, additional, Bensa, Caroline, additional, Louapre, Celine, additional, Benoit, Jeanne, additional, Landes-Chateau, Cassandre, additional, and Lebrun-Frenay, Christine, additional
- Published
- 2023
- Full Text
- View/download PDF
5. Teriflunomide and Time to Clinical Multiple Sclerosis in Patients With Radiologically Isolated Syndrome: The TERIS Randomized Clinical Trial.
- Author
-
Lebrun-Frénay, Christine, Siva, Aksel, Sormani, Maria Pia, Landes-Chateau, Cassandre, Mondot, Lydiane, Bovis, Francesca, Vermersch, Patrick, Papeix, Caroline, Thouvenot, Eric, Labauge, Pierre, Durand-Dubief, Françoise, Efendi, Husnu, Le Page, Emmanuelle, Terzi, Murat, Derache, Nathalie, Bourre, Bertrand, Hoepner, Robert, Karabudak, Rana, De Seze, Jérôme, and Ciron, Jonathan
- Published
- 2023
- Full Text
- View/download PDF
6. Anti-Argonaute antibodies as a potential biomarker in NMOSD
- Author
-
Carta, Sara, primary, Le Duy, Do, additional, Rogemond, Veronique, additional, Derache, Nathalie, additional, Chaumont, Hugo, additional, Fromont, Agnès, additional, Cabasson, Sebastien, additional, Boudot de la Motte, Marine, additional, Honnorat, Jerome, additional, and Marignier, Romain, additional
- Published
- 2023
- Full Text
- View/download PDF
7. No evidence for genetic association between glutamate transporter EAAT2 and Devic's neuromyelitis optica in caucasians and afro-caribbeans
- Author
-
Hanoux, Vincent, Coulbault, Laurent, Derache, Nathalie, Cabre, Philippe, De Seze, Jérôme, Marignier, Romain, Rudolf, Gabrielle, Emmanuelle Dugué, Audrey, Allouche, Stéphane, and Defer, Gilles
- Published
- 2014
- Full Text
- View/download PDF
8. Fatigue is associated with metabolic and density alterations of cortical and deep gray matter in Relapsing-Remitting-Multiple Sclerosis patients at the earlier stage of the disease: A PET/MR study
- Author
-
Derache, Nathalie, Grassiot, Blandine, Mézenge, Florence, Emmanuelle Dugué, Audrey, Desgranges, Béatrice, Constans, Jean-Marc, and Defer, Gilles-Louis
- Published
- 2013
- Full Text
- View/download PDF
9. CD49d expression as a promising biomarker to monitor natalizumab efficacy
- Author
-
Defer, Gilles, Mariotte, Delphine, Derache, Nathalie, Toutirais, Olivier, Legros, Hélène, Cauquelin, Brigitte, and Le Mauff, Brigitte
- Published
- 2012
- Full Text
- View/download PDF
10. Multi-center, Randomized, Double-blinded Assessment of TERIFLUNOMIDE (Aubagio®) in Extending the Time to the First Attack in Radiologically Isolated Syndrome: Baseline Characteristics of the TERIS Study. (P5-4.011)
- Author
-
Frenay, Christine Lebrun, primary, Landes-Château, Cassandre, additional, Siva, Aksel, additional, Sormani, Maria Pia, additional, Mondot, Lydiane, additional, Vermersch, Patrick, additional, Papeix, Anne Caroline, additional, Thouvenot, Eric, additional, Labauge, Pierre, additional, Dubief, Francoise Durand, additional, Efendi, Husnu, additional, Le Page, Emmanuelle, additional, Terzi, Murat, additional, Derache, Nathalie, additional, Bourre, Bertrand, additional, Hoepner, Robert, additional, Karabudak, Rana, additional, De Seze, Jerome, additional, Ciron, Jonathan, additional, Clavelou, Pierre, additional, Wiertlewski, Sandrine, additional, Turan, Omer, additional, Yuceyar, Nur, additional, Cohen, Mikael, additional, Kantarci, Orhun, additional, Pelletier, Daniel, additional, and Okuda, Darin, additional
- Published
- 2022
- Full Text
- View/download PDF
11. Prospective Characterization of Brain T2 Lesions Suggestive of Demyelination in Asymptomatic Patients diagnosed as Radiologically Isolated Syndrome (P14-4.011)
- Author
-
Landes-Château, Cassandre, primary, Mondot, Lydiane, additional, Cohen, Mikael, additional, Callier, Céline, additional, Zephir, Helene, additional, Louapre, Celine, additional, Dubief, Francoise Durand, additional, Carra-Dalliere, Clarisse, additional, Thouvenot, Eric, additional, Le Page, Emmanuelle, additional, Ruet, Aurelie, additional, Berger, Eric, additional, Derache, Nathalie, additional, Clavelou, Pierre, additional, Moreau, Thibault, additional, Casez, Olivier, additional, Gout, Olivier, additional, De Seze, Jerome, additional, Ciron, Jonathan, additional, Wiertlewski, Sandrine, additional, Bourre, Bertrand, additional, Magy, Laurent, additional, Cabre, Philippe, additional, Pelletier, Jean, additional, Debouverie, Marc, additional, Stankoff, Bruno, additional, Creange, Alain, additional, Fagniez, Ombeline, additional, Pottier, Corinne, additional, Neau, Jean Philippe, additional, Camdessanche, Jean-Philippe, additional, Henry, Carole, additional, Beltran, Stephane, additional, Guennoc, Anne Marie, additional, Tourbah, Ayman, additional, Radji, Fatai, additional, Morel, Nathalie, additional, Boyer, Karine, additional, Al Khedr, Abdullatif, additional, Siva, Aksel, additional, Kantarci, Orhun, additional, Pelletier, Daniel, additional, Okuda, Darin, additional, and Lebrun-Frenay, Christine, additional
- Published
- 2022
- Full Text
- View/download PDF
12. Télémédecine et e-santé dans le parcours de soins des patients SEP
- Author
-
Defer, Gilles, primary, Derache, Nathalie, additional, Branger, Pierre, additional, and Arnaud, Charlotte, additional
- Published
- 2022
- Full Text
- View/download PDF
13. Post-vaccine COVID-19 in patients with multiple sclerosis or neuromyelitis optica
- Author
-
Januel, Edouard, primary, De Seze, Jérôme, additional, Vermersch, Patrick, additional, Maillart, Elisabeth, additional, Bourre, Bertrand, additional, Pique, Julie, additional, Moisset, Xavier, additional, Bensa, Caroline, additional, Maarouf, Adil, additional, Pelletier, Jean, additional, Vukusic, Sandra, additional, Audoin, Bertrand, additional, Louapre, Céline, additional, Beltran, Stéphane, additional, Berger, Eric, additional, Bigaut, Kevin, additional, Derache, Nathalie, additional, Gassama, Salimata, additional, Heinzlef, Olivier, additional, Kremer, Laurent, additional, Kerschen, Philippe, additional, Maurousset, Aude, additional, Ricigliano, Vito A G, additional, Garcia, Pierre-Yves, additional, and Labauge, Pierre, additional
- Published
- 2021
- Full Text
- View/download PDF
14. Phenotypic spectrum of probable and genetically-confirmed idiopathic basal ganglia calcification
- Author
-
Nicolas, Gaël, Pottier, Cyril, Charbonnier, Camille, Guyant-Maréchal, Lucie, Le Ber, Isabelle, Pariente, Jérémie, Labauge, Pierre, Ayrignac, Xavier, Defebvre, Luc, Maltête, David, Martinaud, Olivier, Lefaucheur, Romain, Guillin, Olivier, Wallon, David, Chaumette, Boris, Rondepierre, Philippe, Derache, Nathalie, Fromager, Guillaume, Schaeffer, Stéphane, Krystkowiak, Pierre, Verny, Christophe, Jurici, Snejana, Sauvée, Mathilde, Vérin, Marc, Lebouvier, Thibaud, Rouaud, Olivier, Thauvin-Robinet, Christel, Rousseau, Stéphane, Rovelet-Lecrux, Anne, Frebourg, Thierry, Campion, Dominique, Hannequin, Didier, Ahtoy, Patrick, Anheim, Mathieu, Augustin, Jérôme, Ayrignac, Xavier, Bille-Turc, Françoise, Campion, Dominique, Chaumette, Boris, Clanet, Michel, Defebvre, Luc, Defer, Gilles, Derache, Nathalie, Didic, Mira, Durif, Franck, Flamand-Roze, Emmanuel, Fromager, Guillaume, Giroud, Maurice, Goldenberg, Alice, Guillin, Olivier, Guyant-Maréchal, Lucie, Hannequin, Didier, Hubsch, Cécile, Jurici, Snejana, Krystkowiak, Pierre, Labauge, Pierre, Layet, Antoine, Le Ber, Isabelle, Lebouvier, Thibaud, Lefaucheur, Romain, Maltête, David, Morcamp, Olivier Martinaud Donald, Nicolas, Gaël, Ozkul, Ozlem, Pariente, Jérémie, Pottier, Cyril, Rondepierre, Philippe, Rouaud, Olivier, Sallé, Brigitte, Sauvée, Mathilde, Schaeffer, Stéphane, Thauvin-Robinet, Christel, Thomas-Antérion, Catherine, Tranchant, Christine, Triquenot, Aude, Vaschalde, Yvan, Vérin, Marc, Verny, Christophe, Vidailhet, Marie, and Wallon, David
- Published
- 2013
- Full Text
- View/download PDF
15. Adult-onset genetic leukoencephalopathies: A MRI pattern-based approach in a comprehensive study of 154 patients
- Author
-
Ayrignac, Xavier, Carra-Dalliere, Clarisse, Menjot de Champfleur, Nicolas, Denier, Christian, Aubourg, Patrick, Bellesme, Celine, Castelnovo, Giovanni, Pelletier, Jean, Audoin, Bertrand, Kaphan, Elsa, de Seze, Jerome, Collongues, Nicolas, Blanc, Frederic, Chanson, Jean-Baptiste, Magnin, Eloi, Berger, Eric, Vukusic, Sandra, Durand-Dubief, Francoise, Camdessanche, Jean-Philippe, Cohen, Mickael, Lebrun-Frenay, Christine, Brassat, David, Clanet, Michel, Vermersch, Patrick, Zephir, Helene, Outteryck, Olivier, Wiertlewski, Sandrine, Laplaud, David-Axel, Ouallet, Jean-Christophe, Brochet, Bruno, Goizet, Cyril, Debouverie, Marc, Pittion, Sophie, Edan, Gilles, Deburghgraeve, Véronique, Le Page, Emmanuelle, Verny, Christophe, Amati-Bonneau, Patrizia, Bonneau, Dominique, Hannequin, Didier, Guyant-Maréchal, Lucie, Derache, Nathalie, Louis Defer, Gilles, Moreau, Thibault, Giroud, Maurice, Guennoc, Anne Marie, Clavelou, Pierre, Taithe, Frédérique, Mathis, Stephane, Neau, Jean-Philippe, Magy, Laurent, Devoize, Jean Louis, Bataillard, Marc, Masliah-Planchon, Julien, Dorboz, Imen, Tournier-Lasserve, Elisabeth, Levade, Thierry, Boespflug Tanguy, Odile, and Labauge, Pierre
- Published
- 2015
- Full Text
- View/download PDF
16. Heterozygous HTRA1 nonsense or frameshift mutations are pathogenic
- Author
-
Coste, Thibault, primary, Hervé, Dominique, additional, Neau, Jean Philippe, additional, Jouvent, Eric, additional, Ba, Fatoumata, additional, Bergametti, Françoise, additional, Lamy, Matthias, additional, Cogez, Julien, additional, Derache, Nathalie, additional, Schneckenburger, Romain, additional, Grelet, Maude, additional, Gollion, Cédric, additional, Lanotte, Livia, additional, Lauer, Valérie, additional, Layet, Valérie, additional, Urbanczyk, Cédric, additional, Didic, Mira, additional, Raynouard, Igor, additional, Delaval, Laure, additional, Dassa, Jérémie, additional, Florea, Alexandru, additional, Badiu, Carmen, additional, Nguyen, Karine, additional, and Tournier-Lasserve, Elisabeth, additional
- Published
- 2021
- Full Text
- View/download PDF
17. Severe bone pain with teriflunomide: Five case reports and review of the French pharmacovigilance database
- Author
-
Peyro-Saint-Paul, Laure, Derache, Nathalie, Ficheux, Maxence, Allouche, Stéphane, Parienti, Jean-Jacques, Calocer, Floriane, Le Caignec, Florian, Fedrizzi, Sophie, and Defer, Gilles
- Published
- 2020
- Full Text
- View/download PDF
18. The detection of antithyroid antibodies in cerebrospinal fluid using fluorescent enzyme immuno assay (FEIA) is suitable for biological diagnosis of Hashimoto's encephalopathy
- Author
-
Serrier, Julien, additional, Branger, Pierre, additional, Gondolf, Clémentine, additional, Khoy, Kathy, additional, Derache, Nathalie, additional, Le Mauff, Brigitte, additional, Comby, Elisabeth, additional, and Mariotte, Delphine, additional
- Published
- 2021
- Full Text
- View/download PDF
19. BEST-MS: A prospective head-to-head comparative study of natalizumab and fingolimod in active relapsing MS
- Author
-
Cohen, Mikael, Mondot, Lydiane, Bucciarelli, Florence, Pignolet, Béatrice, Laplaud, David-Axel, Wiertlewski, Sandrine, Brochet, Bruno, Ruet, Aurélie, Defer, Gilles, Derache, Nathalie, Vermersch, Patrick, Zephir, Hélène, Debouverie, Marc, Mathey, Guillaume, Berger, Eric, Cappé, Chrystelle, Labauge, Pierre, Carra, Clarisse, de Seze, Jérôme, Bigaut, Kevin, Brassat, David, Lebrun-Frenay, Christine, Service de Neurologie [CHU Nice], Hôpital Pasteur [Nice] (CHU)-Centre Hospitalier Universitaire de Nice (CHU Nice), Hôpital Pasteur [Nice] (CHU), Pôle Neurosciences [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Centre de Physiopathologie Toulouse Purpan (CPTP), Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre de Recherche en Transplantation et Immunologie (U1064 Inserm - CRTI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN), Centre d’Investigation Clinique de Nantes (CIC Nantes), Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre hospitalier universitaire de Nantes (CHU Nantes), Service de neurologie [Nantes], Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Hôpital Guillaume-et-René-Laennec [Saint-Herblain], Service de neurologie [Bordeaux], CHU Bordeaux [Bordeaux]-Groupe hospitalier Pellegrin, Service de Neurologie [CHU Caen], Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN), Lille Neurosciences & Cognition - U 1172 (LilNCog), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Centre d'investigation clinique - Epidémiologie clinique [Nancy] (CIC-EC), Centre d'investigation clinique [Nancy] (CIC), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL)-Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Service de Neurologie [CHRU Besançon], Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Centre d'Investigation Clinique de Besançon (Inserm CIC 1431), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Etablissement français du sang [Bourgogne-Franche-Comté] (EFS BFC)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), CHU Montpellier, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Université de Montpellier (UM), CIC Strasbourg (Centre d’Investigation Clinique Plurithématique (CIC - P) ), Université de Strasbourg (UNISTRA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Nouvel Hôpital Civil de Strasbourg-Hôpital de Hautepierre [Strasbourg], Service de Neurologie [Strasbourg], and CHU Strasbourg-Hopital Civil
- Subjects
MESH: Humans ,[SDV]Life Sciences [q-bio] ,MESH: Multiple Sclerosis ,MESH: Natalizumab / therapeutic use ,MESH: Prospective Studies ,Multiple sclerosis ,MESH: Fingolimod Hydrochloride* / therapeutic use ,natalizumab ,[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases ,therapeutics ,magnetic resonance imaging ,[SDV.IMM]Life Sciences [q-bio]/Immunology ,fingolimod ,MESH: Neoplasm Recurrence, Local - Abstract
International audience; Background: There are few head-to-head studies to compare highly active treatments in multiple sclerosis (MS) Objective: The aim of this study was to compare the effectiveness between natalizumab (NTZ) and fingolimod (FTY) in active relapsing–remitting MS Method: Best Escalation STrategy in Multiple Sclerosis (BEST-MS) is a multicentric, prospective study with a 12-month follow-up including patients with active MS. Treatment choice was at the discretion of physician. Clinical and magnetic resonance imaging (MRI) data were collected at baseline and at 12 months. The primary outcome was the proportion of patients reaching no evidence of disease activity (NEDA) at 12 months. Secondary outcomes included annualized relapse rate and MRI activity. Results: A total of 223 patients were included (NTZ: 109 and FTY: 114). Treatment groups were well balanced at baseline. Proportion of NEDA patients was 47.8% in NTZ group versus 30.4% in FTY group ( p = 0.015). This superiority was driven by annualized relapse rate and MRI activity. In the multivariate analysis, treatment group was the only factor associated with NEDA at 12 months with a lower probability in FTY group (odds ratio (OR) = 0.49, p = 0.029). Conclusion: BEST-MS is a prospective study that compared head-to-head the effectiveness of NTZ and FTY in active relapsing–remitting MS. Our results suggest a superiority of NTZ over FTY.
- Published
- 2020
- Full Text
- View/download PDF
20. Neurologic manifestations associated with COVID-19: a multicentre registry
- Author
-
Meppiel, Elodie, primary, Peiffer-Smadja, Nathan, additional, Maury, Alexandra, additional, Bekri, Imen, additional, Delorme, Cécile, additional, Desestret, Virginie, additional, Gorza, Lucas, additional, Hautecloque-Raysz, Geoffroy, additional, Landre, Sophie, additional, Lannuzel, Annie, additional, Moulin, Solène, additional, Perrin, Peggy, additional, Petitgas, Paul, additional, SellaI, François, additional, Wang, Adrien, additional, Tattevin, Pierre, additional, de Broucker, Thomas, additional, Abgrall, Sophie, additional, Alby-Laurent, Fanny, additional, Allou, Thibault, additional, Amevigbe, Joséphine, additional, Amarguellay, Hanifa, additional, Alloussi, Nabil, additional, Baille, Guillaume, additional, Barbaz, Mathilde, additional, Bencherif, Lamia, additional, Bensaadi, Samia, additional, Beraud, Guillaume, additional, Bizot, Alexandra, additional, Bottin, Laure, additional, Bruneel, Fabrice, additional, Camdessanche, Jean-Philippe, additional, Chauffier, Jeanne, additional, Csajaghy, Jean-Philippe, additional, De Broucker, Chloé, additional, De Broucker, Thomas, additional, Defebvre, Luc, additional, Dembloque, Elodie, additional, Derache, Nathalie, additional, Dereeper, Olivier, additional, Derollez, Céline, additional, Descotes-Genon, Cécile, additional, Devaux, Mathilde, additional, Dubuc, Lydie, additional, Edan, Gilles, additional, Fickl, Andréa, additional, Fraisse, Thibault, additional, Gugenheim, Michel, additional, Hankiewicz, Karolina, additional, Hansmann, Yves, additional, Henry, Carole, additional, Jobard, Stéphanie, additional, Jouan, Fanny, additional, Kwiatkowski, Arnaud, additional, Lalu, Thibault, additional, Leguilloux, Johan, additional, Lejeune, Camille, additional, Liegeois, Clémence, additional, Mahy, Sophie, additional, Marey, Jonathan, additional, Meppiel, Elodie, additional, Michel, Laure, additional, Mitri, Rita, additional, Moulin, Chloé, additional, Omarjee, Asma, additional, Ozsancak, Canan, additional, Pico, Fernando, additional, Poupard, Marie, additional, Rabier, Valérie, additional, Rizzato, Camille, additional, Roos, Caroline, additional, Saison, Julien, additional, Sayre, Naomi, additional, Sedillot, Nicolas, additional, Sellal, François, additional, Servan, Jérôme, additional, Storey, Caroline, additional, Suchet, Laurent, additional, Tarteret, Paul, additional, Thiebaut, Mathilde, additional, Vaduva, Claudia, additional, Varlan, David, additional, and Zarrouk, Virginie, additional
- Published
- 2021
- Full Text
- View/download PDF
21. Post-vaccine COVID-19 in patients with multiple sclerosis or neuromyelitis optica.
- Author
-
Januel, Edouard, De Seze, Jérôme, Vermersch, Patrick, Maillart, Elisabeth, Bourre, Bertrand, Pique, Julie, Moisset, Xavier, Bensa, Caroline, Maarouf, Adil, Pelletier, Jean, Vukusic, Sandra, Audoin, Bertrand, Louapre, Céline, Beltran, Stéphane, Berger, Eric, Bigaut, Kevin, Derache, Nathalie, Gassama, Salimata, Heinzlef, Olivier, and Kremer, Laurent
- Subjects
NEUROMYELITIS optica ,COVID-19 ,MULTIPLE sclerosis ,VACCINE effectiveness ,COVID-19 vaccines - Abstract
Introduction: Recent studies suggested that anti-CD20 and fingolimod may be associated with lower anti-spike protein-based immunoglobulin-G response following COVID-19 vaccination. We evaluated if COVID-19 occurred despite vaccination among patients with multiple sclerosis (MS) and neuromyelitis optica (NMO), using the COVISEP registry. Case series: We report 18 cases of COVID-19 after two doses of BNT162b2-vaccination, 13 of which treated with anti-CD20 and four with fingolimod. COVID-19 severity was mild. Discussion: These results reinforce the recommendation for a third COVID-19 vaccine dose among anti-CD20 treated patients and stress the need for a prospective clinical and biological study on COVID-19 vaccine efficacy among MS and NMO patients. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
22. Reduced thalamic and cerebellar rest metabolism in relapsing–remitting multiple sclerosis, a positron emission tomography study: Correlations to lesion load
- Author
-
Derache, Nathalie, Marié, Rose-Marie, Constans, Jean-Marc, and Defer, Gilles-Louis
- Published
- 2006
- Full Text
- View/download PDF
23. Relapsing polychondritis revealed by basal ganglia lesions
- Author
-
Defer, Gilles-Louis, Danaila, Teodor, Constans, Jean Marc, and Derache, Nathalie
- Published
- 2012
- Full Text
- View/download PDF
24. Forme sévère d’angiopathie amyloïde cérébrale inflammatoire atypique chez une jeune femme : à propos d’un cas
- Author
-
La Porte, Estelle, primary, Branger, Pierre, additional, Chapon, Françoise, additional, Martinaud, Olivier, additional, and Derache, Nathalie, additional
- Published
- 2020
- Full Text
- View/download PDF
25. BEST-MS: A Standardized and Prospective Study Comparing the Efficacy of Natalizumab versus Fingolimod in Active Relapsing Multiple Sclerosis. (769)
- Author
-
Cohen, Mikael, primary, Mondot, Lydiane, additional, BUCCIARELLI, Florence, additional, PIGNOLET, Béatrice, additional, LAPLAUD, David, additional, Brochet, Bruno, additional, Defer, Gilles, additional, Derache, Nathalie, additional, Vermersch, Patrick, additional, ZEPHIR, Hélène, additional, Debouverie, Marc, additional, Berger, Eric, additional, Labauge, Pierre, additional, Ayrignac, Xavier, additional, De Seze, Jerome, additional, Brassat, David, additional, and Lebrun-Frenay, Christine, additional
- Published
- 2020
- Full Text
- View/download PDF
26. Biallelic MYORG mutation carriers exhibit primary brain calcification with a distinct phenotype
- Author
-
Grangeon, Lou, Charbonnier, Camille, Quenez, Olivier, Rousseau, Stéphane, Budowski, Clara, Corbillé, Anne-Gaëlle, Antoine, Jean-Christophe, Clanet, Michel, Rovelet-Lecrux, Anne, Boland, Anne, Deleuze, Jean-François, Favrole, Pascal, Verny, Christophe, Krystkowiak, Pierre, Chamard, Ludivine, Moutton, Sébastien, Goizet, Cyril, Ferec, Claude, Timsit, Serge, Schaeffer, Stéphane, Derache, Nathalie, Defer, Gilles, Durif, Franck, Sellal, François, Rouaud, Olivier, Thauvin-Robinet, Christel, Cubizolle, Stéphanie, Sauvée, Mathilde, Leblanc, Amélie, Demas, Alexis, POISSON, Alice, Tournier-Lasserve, Elisabeth, Hervé, Dominique, Chabriat, Hugues, Grolez, Guillaume, Carrière, Nicolas, Defebvre, Luc, Lebouvier, Thibaud, Witjas, Tatiana, Azulay, Jean-Philippe, Fluchère, Frédérique, Didic, Mira, Nguyen, Karine, Charif, Mahmoud, Ayrignac, Xavier, Labauge, Pierre, Lionnet, Caroline, Marelli-Tosi, Cecilia, GAUD, Simon, Rouaud, Tiphaine, Laurens, Brice, Folgoas, Emmanuelle, Isidor, Bertrand, Chiesa, Jean, Pallix-Guyot, Maud, Gaillard, Nicolas, Olivier, Nadège, Jurici, Snejana, Marey, Isabelle, Charles, Perrine, Ewenczyck, Claire, Dürr, Alexandra, Hubsch, Cécile, Méneret, Aurélie, Vidailhet, Marie, Nadjar, Yann, Le Ber, Isabelle, Grabli, David, Roze, Emmanuel, Navarro, Vincent, Mecharles-Darrigol, Sylvie, Lagarde, Julien, Sarazin, Marie, Vérin, Marc, Lefaucheur, Romain, Maltête, David, Wallon, David, Martinaud, Olivier, Guyant-Maréchal, Lucie, Richard, Anne-claire, Guillin, Olivier, Yger, Marion, Anheim, Mathieu, Renaud, Mathilde, Tranchant, Christine, Rudolf, Gabrielle, Cretin, Benjamin, Mallaret, Martial, Pariente, Jérémie, Ory-Magne, Fabienne, Frebourg, Thierry, Hannequin, Didier, Campion, Dominique, Nicolas, Gaël, UNIROUEN - UFR Santé (UNIROUEN UFR Santé), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU), Génomique et Médecine Personnalisée du Cancer et des Maladies Neuropsychiatriques (GPMCND), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut du Fer à Moulin, Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Pierre et Marie Curie - Paris 6 (UPMC), Service de Neurologie, CHU Saint-Etienne-Hôpital Bellevue, Hôpital Purpan [Toulouse], CHU Toulouse [Toulouse], Centre National de Génotypage (CNG), Commissariat à l'énergie atomique et aux énergies alternatives (CEA), Biologie Neurovasculaire Intégrée (BNVI), Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université d'Angers (UA), Service de neurochirurgie générale et stéréotaxique fonctionnelle, Hôpital Roger Salengro-Université de Lille, Droit et Santé-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Centre Mémoire de Ressources et de Recherche - CMRR [Besançon] (CMRR), Centre Hospitalier Régional Universitaire [Besançon] (CHRU Besançon), Centre de génétique - Centre de référence des maladies rares, anomalies du développement et syndromes malformatifs (CHU de Dijon), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Service de génétique médicale, Université de Bordeaux (UB)-CHU Bordeaux [Bordeaux]-Groupe hospitalier Pellegrin, Génétique moléculaire et génétique épidémiologique, Université de Brest (UBO)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de Neurologie [Brest], Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN), Service de Neurologie [CHU Caen], Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN), Service de neurologie, Hôpital Gabriel Montpied, Hôpital pasteur [Colmar], Université Montpellier 1 (UM1)-Hôpital Guy de Chauliac-Centre Mémoire Ressources Recherche Languedoc - Roussillon, Centre Hospitalier Universitaire [Grenoble] (CHU), Hôpital d'Instruction des Armées 'Clermont-Tonnerre' (HIA), Institut des sciences cognitives Marc Jeannerod - Centre de neuroscience cognitive - UMR5229 (CNC), Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon, Genetique des Maladies Vasculaires, Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM), Gouvernance, Risque, Environnement, Développement (GRED), Université Paul-Valéry - Montpellier 3 (UM3)-Institut de Recherche pour le Développement (IRD [France-Sud])-Institut national d’études supérieures agronomiques de Montpellier (Montpellier SupAgro), Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Service de neurologie et pathologie du mouvement, Hôpital Roger Salengro-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Troubles cognitifs dégénératifs et vasculaires (U1171), INSERM-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)-Université de Lille, Neuropathies du système nerveux entérique et pathologies digestives, implication des cellules gliales entériques, Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital de la Timone [CHU - APHM] (TIMONE), Laboratoire de Neurosciences Cognitives [Marseille] (LNC), Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS), Service de neurologie et de neuropsychologie, Université de la Méditerranée - Aix-Marseille 2-Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital de la Timone [CHU - APHM] (TIMONE), Marseille medical genetics - Centre de génétique médicale de Marseille (MMG), Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Institut des Neurosciences de Montpellier - Déficits sensoriels et moteurs (INM), Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital Gui de Chauliac, Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Département de neurologie [Montpellier], Hôpital Gui de Chauliac [Montpellier]-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Université Montpellier 1 (UM1)-Université de Montpellier (UM), Université de Lorraine (UL), Service de neurologie [Rennes], Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES), Université de Bordeaux (UB), Service de génétique médicale - Unité de génétique clinique [Nantes], Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes), Centre Hospitalier Régional Universitaire de Nîmes (CHRU Nîmes), Centre Hospitalier Régional d'Orléans (CHR), Service de génétique, cytogénétique, embryologie [Pitié-Salpétrière], Université Pierre et Marie Curie - Paris 6 (UPMC)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Pitié-Salpêtrière [APHP], Centre de Recherche de l'Institut du Cerveau et de la Moelle épinière (CRICM), Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Pierre et Marie Curie - Paris 6 (UPMC), CHU Pitié-Salpêtrière [APHP], Institut du Cerveau et de la Moëlle Epinière = Brain and Spine Institute (ICM), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [APHP]-Centre National de la Recherche Scientifique (CNRS), Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS)-CHU Pitié-Salpêtrière [APHP]-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de neurologie 1 [CHU Pitié-Salpétrière], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Pitié-Salpêtrière [APHP], Fédération des Maladies du Système Nerveux, Laboratoire de neurosciences cognitives et d'imagerie cérébrale (LENA), Centre National de la Recherche Scientifique (CNRS)-Université Pierre et Marie Curie - Paris 6 (UPMC), Efficience Déficience Motrice [Montpellier] (EDM), Université Montpellier 1 (UM1), Service de neurologie [Rouen], CHU Rouen, Normandie Université (NU), Service des Urgences Cérébro-Vasculaires [CHU Pitié-Salpêtrière]], CHU Pitié-Salpêtrière [APHP]-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), CHU Strasbourg, Département de Neurologie, CHU Strasbourg-Hopital Civil, Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université de Strasbourg (UNISTRA), Laboratoire des sciences de l'ingénieur, de l'informatique et de l'imagerie (ICube), École Nationale du Génie de l'Eau et de l'Environnement de Strasbourg (ENGEES)-Université de Strasbourg (UNISTRA)-Institut National des Sciences Appliquées - Strasbourg (INSA Strasbourg), Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Centre National de la Recherche Scientifique (CNRS)-Matériaux et nanosciences d'Alsace, Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Haute-Alsace (UHA) Mulhouse - Colmar (Université de Haute-Alsace (UHA))-Université de Strasbourg (UNISTRA)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Haute-Alsace (UHA) Mulhouse - Colmar (Université de Haute-Alsace (UHA))-Université de Strasbourg (UNISTRA)-Réseau nanophotonique et optique, Centre National de la Recherche Scientifique (CNRS)-Université de Strasbourg (UNISTRA)-Université de Haute-Alsace (UHA) Mulhouse - Colmar (Université de Haute-Alsace (UHA))-Université de Strasbourg (UNISTRA), Imagerie cérébrale et handicaps neurologiques, Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut des sciences du cerveau de Toulouse. (ISCT), Université Toulouse - Jean Jaurès (UT2J)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-CHU Toulouse [Toulouse]-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Toulouse - Jean Jaurès (UT2J)-CHU Toulouse [Toulouse]-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), CIC Toulouse, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Département de neurologie [Lille], Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Service de neurologie [Nantes], Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Hôpital Guillaume-et-René-Laennec [Saint-Herblain], Institut du Cerveau = Paris Brain Institute (ICM), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Fédération de Médecine Translationnelle de Strasbourg (FMTS), Université de Strasbourg (UNISTRA), Université de Strasbourg (UNISTRA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Service de Neurologie [Aix-en-Provence], Centre Hospitalier du Pays d'Aix, Service de Neurologie [CHU de Saint-Étienne], Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] (CHU ST-E)-Université Jean Monnet - Saint-Étienne (UJM), Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Hôpital Gui de Chauliac [CHU Montpellier], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Université de Montpellier (UM), Neurologie Vasculaire [Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Différenciation et communication neuronale et neuroendocrine (DC2N), Institut de Biologie François JACOB (JACOB), Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA), ANR-17-CE14-0008,CALCIPHOS,ROLE DE L'EXPORTATEUR DE PHOSPHATE DANS LA CALCIFICATION VASCULAIRE(2017), Département de neurologie[Lille], Université de Lille, Droit et Santé-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [APHP]-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Service de neurologie [CHU de Saint-Étienne], Centre Hospitalier Universitaire de Saint-Etienne (CHU de Saint-Etienne), Laboratoire de Neurosciences Fonctionnelles et Pathologies, Hôpital Roger Salengro-PRES Université Lille Nord de France-EA 4559/1046-Université de Lille, Droit et Santé, Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-CHU Toulouse [Toulouse]-Hôpital de Rangueil, Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Laboratoire de Neurosciences Fonctionnelles et Pathologies - UR UPJV 4559 (LNFP), Université de Picardie Jules Verne (UPJV), Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Hôpital Gui de Chauliac [Montpellier]-Université de Montpellier (UM), and Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)
- Subjects
0301 basic medicine ,Proband ,Adult ,Male ,Pathology ,medicine.medical_specialty ,Heterozygote ,Glycoside Hydrolases ,[SDV]Life Sciences [q-bio] ,PDGFRB ,medicine.disease_cause ,Nervous System Malformations ,MESH: phenotype, computed tomography, mutation, genes, pons, brain, autosomal recessive inheritance, cerebellar atrophy, calcification ,03 medical and health sciences ,Young Adult ,0302 clinical medicine ,medicine ,Humans ,ComputingMilieux_MISCELLANEOUS ,Mutation ,Brain Diseases ,PDGFB ,business.industry ,Brain ,Calcinosis ,Middle Aged ,medicine.disease ,Penetrance ,3. Good health ,Pedigree ,030104 developmental biology ,Phenotype ,Cerebellar atrophy ,Female ,Neurology (clinical) ,Age of onset ,business ,Xenotropic and Polytropic Retrovirus Receptor ,030217 neurology & neurosurgery ,Calcification - Abstract
International audience; Primary familial brain calcification (PFBC) is a rare neurogenetic disorder with diverse neuropsychiatric expression. Mutations in four genes cause autosomal dominant PFBC: SLC20A2, XPR1, PDGFB and PDGFRB. Recently, biallelic mutations in the MYORG gene have been reported to cause PFBC with an autosomal recessive pattern of inheritance. We screened MYORG in 29 unrelated probands negatively screened for the autosomal dominant PFBC genes and identified 11 families with a biallelic rare or novel predicted damaging variant. We studied the clinical and radiological features of 16 patients of these 11 families and compared them to that of 102 autosomal dominant PFBC patients carrying a mutation in one of the four known autosomal dominant PFBC genes. We found that MYORG patients exhibited a high clinical penetrance with a median age of onset of 52 years (range: 21–62) with motor impairment at the forefront. In particular, dysarthria was the presenting sign in 11/16 patients. In contrast to patients with autosomal dominant PFBC, 12/15 (80%) symptomatic patients eventually presented at least four of the following five symptoms: dysarthria, cerebellar syndrome, gait disorder of any origin, akinetic-hypertonic syndrome and pyramidal signs. In addition to the most severe clinical pattern, MYORG patients exhibited the most severe pattern of calcifications as compared to the patients from the four autosomal dominant PFBC gene categories. Strikingly, 12/15 presented with brainstem calcifications in addition to extensive calcifications in other brain areas (lenticular nuclei, thalamus, cerebellar hemispheres, vermis, ±cortex). Among them, eight patients exhibited pontine calcifications, which were observed in none of the autosomal dominant PFBC patients and hence appeared to be highly specific. Finally, all patients exhibited cerebellar atrophy with diverse degrees of severity on CT scans. We confirmed the existence of cerebellar atrophy by performing MRI voxel-based morphometry analyses of MYORG patients with autosomal dominant PFBC mutation carriers as a comparison group. Of note, in three families, the father carried small pallido-dentate calcifications while carrying the mutation at the heterozygous state, suggesting a putative phenotypic expression in some heterozygous carriers. In conclusion, we confirm that MYORG is a novel major PFBC causative gene and that the phenotype associated with such mutations may be recognized based on pedigree, clinical and radiological features.
- Published
- 2019
- Full Text
- View/download PDF
27. MSJ849511_supplemental_figure – Supplemental material for Frequency and characteristics of short versus longitudinally extensive myelitis in adults with MOG antibodies: A retrospective multicentric study
- Author
-
Ciron, Jonathan, Cobo-Calvo, Alvaro, Audoin, Bertrand, Bourre, Bertrand, Brassat, David, Cohen, Mikael, Collongues, Nicolas, Deschamps, Romain, Durand-Dubief, Françoise, Laplaud, David, Maillart, Elisabeth, Papeix, Caroline, Zephir, Hélène, Bereau, Matthieu, Brochet, Bruno, Carra-Dallière, Clarisse, Derache, Nathalie, Gagou-Scherer, Clarisse, Henry, Carole, Kerschen, Philippe, Mathey, Guillaume, Maubeuge, Nicolas, Maurousset, Aude, Montcuquet, Alexis, Moreau, Thibault, Prat, Christophe, Taithe, Frédéric, Thouvenot, Eric, Tourbah, Ayman, Rollot, Fabien, Vukusic, Sandra, and Marignier, Romain
- Subjects
FOS: Clinical medicine ,111702 Aged Health Care ,FOS: Health sciences ,110904 Neurology and Neuromuscular Diseases - Abstract
Supplemental material, MSJ849511_supplemental_figure for Frequency and characteristics of short versus longitudinally extensive myelitis in adults with MOG antibodies: A retrospective multicentric study by Jonathan Ciron, Alvaro Cobo-Calvo, Bertrand Audoin, Bertrand Bourre, David Brassat, Mikael Cohen, Nicolas Collongues, Romain Deschamps, Françoise Durand-Dubief, David Laplaud, Elisabeth Maillart, Caroline Papeix, Hélène Zephir, Matthieu Bereau, Bruno Brochet, Clarisse Carra-Dallière, Nathalie Derache, Clarisse Gagou-Scherer, Carole Henry, Philippe Kerschen, Guillaume Mathey, Nicolas Maubeuge, Aude Maurousset, Alexis Montcuquet, Thibault Moreau, Christophe Prat, Frédéric Taithe, Eric Thouvenot, Ayman Tourbah, Fabien Rollot, Sandra Vukusic and and Romain Marignier in Multiple Sclerosis Journal
- Published
- 2019
- Full Text
- View/download PDF
28. BEST-MS: A prospective head-to-head comparative study of natalizumab and fingolimod in active relapsing MS.
- Author
-
Cohen, Mikael, Mondot, Lydiane, Bucciarelli, Florence, Pignolet, Béatrice, Laplaud, David-Axel, Wiertlewski, Sandrine, Brochet, Bruno, Ruet, Aurélie, Defer, Gilles, Derache, Nathalie, Vermersch, Patrick, Zephir, Hélène, Debouverie, Marc, Mathey, Guillaume, Berger, Eric, Cappé, Chrystelle, Labauge, Pierre, Carra, Clarisse, De Seze, Jérôme, and Bigaut, Kevin
- Subjects
NATALIZUMAB ,MAGNETIC resonance imaging ,PHYSICIANS ,FINGOLIMOD - Abstract
Background: There are few head-to-head studies to compare highly active treatments in multiple sclerosis (MS) Objective: The aim of this study was to compare the effectiveness between natalizumab (NTZ) and fingolimod (FTY) in active relapsing–remitting MS Method: Best Escalation STrategy in Multiple Sclerosis (BEST-MS) is a multicentric, prospective study with a 12-month follow-up including patients with active MS. Treatment choice was at the discretion of physician. Clinical and magnetic resonance imaging (MRI) data were collected at baseline and at 12 months. The primary outcome was the proportion of patients reaching no evidence of disease activity (NEDA) at 12 months. Secondary outcomes included annualized relapse rate and MRI activity. Results: A total of 223 patients were included (NTZ: 109 and FTY: 114). Treatment groups were well balanced at baseline. Proportion of NEDA patients was 47.8% in NTZ group versus 30.4% in FTY group (p = 0.015). This superiority was driven by annualized relapse rate and MRI activity. In the multivariate analysis, treatment group was the only factor associated with NEDA at 12 months with a lower probability in FTY group (odds ratio (OR) = 0.49, p = 0.029). Conclusion: BEST-MS is a prospective study that compared head-to-head the effectiveness of NTZ and FTY in active relapsing–remitting MS. Our results suggest a superiority of NTZ over FTY. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
29. Inflammatory-like presentation of CADASIL: a diagnostic challenge
- Author
-
Collongues Nicolas, Derache Nathalie, Blanc Frédéric, Labauge Pierre, de Seze Jérôme, and Defer Gilles
- Subjects
CADASIL ,Multiple sclerosis ,Leukoencephalopathy ,Notch3 ,Cerebral vasculitis ,Neurology. Diseases of the nervous system ,RC346-429 - Abstract
Abstract Background CADASIL is an autosomal dominant genetic leukoencephalopathy linked to mutations in the Notch3 gene. In rare cases, widespread brain lesions on T2 MRI mimicking multiple sclerosis are observed. From a national registry of 268 patients with adult-onset leukodystrophy, we identified two patients with an atypical presentation of CADASIL without co-occurrence of another systemic disease. Case presentations Patient 1 experienced progressive gait disability and patient 2 relapsing optic neuritis and sensory-motor deficit in the leg. Both patients responded to corticotherapy and patient 2 was also responsive to glatiramer acetate. No oligoclonal bands were found in the CSF, and MRI showed myelitis and lesions with gadolinium enhancement in brain (patient 1) or incomplete CADASIL phenotype (patient 2). Conclusions In rare cases, an inflammatory-like process can occur in CADASIL. In these patients, immunomodulatory treatments, including corticosteroids, could be effective.
- Published
- 2012
- Full Text
- View/download PDF
30. Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults
- Author
-
Cobo-Calvo, Alvaro, Ruiz, Anne, Maillart, Elisabeth, Audoin, Bertrand, Zephir, Helene, Bourre, Bertrand, Ciron, Jonathan, Collongues, Nicolas, Brassat, David, Cotton, Francois, Papeix, Caroline, Durand-Dubief, Francoise, Laplaud, David, Deschamps, Romain, Cohen, Mikaël, Biotti, Damien, Ayrignac, Xavier, Tilikete, Caroline, Thouvenot, Eric, Brochet, Bruno, Dulau, Cecile, Moreau, Thibault, Tourbah, Ayman, Lebranchu, Pierre, Michel, Laure, Lebrun-Frenay, Christine, Montcuquet, Alexis, Mathey, Guillaume, Debouverie, Marc, Pelletier, Jean, Labauge, Pierre, Derache, Nathalie, Coustans, Marc, Rollot, Fabien, De Seze, Jerome, Vukusic, Sandra, Marignier, Romain, Biopathologie de la Myéline, Neuroprotection et Stratégies Thérapeutiques (BMNST), and Université de Strasbourg (UNISTRA)-Institut National de la Santé et de la Recherche Médicale (INSERM)
- Subjects
[SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC] - Published
- 2018
- Full Text
- View/download PDF
31. Frequency and characteristics of short versus longitudinally extensive myelitis in adults with MOG antibodies: A retrospective multicentric study
- Author
-
Ciron, Jonathan, primary, Cobo-Calvo, Alvaro, additional, Audoin, Bertrand, additional, Bourre, Bertrand, additional, Brassat, David, additional, Cohen, Mikael, additional, Collongues, Nicolas, additional, Deschamps, Romain, additional, Durand-Dubief, Françoise, additional, Laplaud, David, additional, Maillart, Elisabeth, additional, Papeix, Caroline, additional, Zephir, Hélène, additional, Bereau, Matthieu, additional, Brochet, Bruno, additional, Carra-Dallière, Clarisse, additional, Derache, Nathalie, additional, Gagou-Scherer, Clarisse, additional, Henry, Carole, additional, Kerschen, Philippe, additional, Mathey, Guillaume, additional, Maubeuge, Nicolas, additional, Maurousset, Aude, additional, Montcuquet, Alexis, additional, Moreau, Thibault, additional, Prat, Christophe, additional, Taithe, Frédéric, additional, Thouvenot, Eric, additional, Tourbah, Ayman, additional, Rollot, Fabien, additional, Vukusic, Sandra, additional, and Marignier, Romain, additional
- Published
- 2019
- Full Text
- View/download PDF
32. Treating asymptomatic bacteriuria before immunosuppressive therapy during multiple sclerosis: Should we do it?
- Author
-
Rouzaud, Claire, Hautecoeur, Patrick, Donze, Cécile, Heinzlef, Olivier, Dinh, Aurélien, Creange, Alain, Abdullatif, Alkhedr, Audouin, Bertrand, Tourbah, Ayman, Berger, Eric, Bourre, Bertrand, Brochet, Bruno, Mekies, Claude, Cabre, Philippe, Papeix, Caroline, Casez, Olivier, Brassat, David, Defer, Gilles, Derache, Nathalie, De Seze, Jérôme, Dive, Dominique, LePage, Emmanuelle, Fromont, Agnes, Gouider, Riadh, Edan, Gilles, Pelletier, Jean, Grimaud, Jérôme, Guennoc, Anne-Marie, Camdessanché, Jean-Philippe, Kwiatkowski, Arnaud, Laplaud, David, Lebrun, Christine, Debouverie, Marc, Coustans, Marc, Gout, Olivier, La Rochelle, Olivier Anne, Ouallet, Jean-Christophe, Cavelou, Pierre, Labauge, Pierre, Vermersch, Patrick, Wiertlewski, Sandrine, Vukusic, Sandra, Marignier, Romain, Schluep, Myriam, Seeldrayers, Pierrette, Slassi, Ilham, Stankoff, Bruno, Thaite, Frederic, Moreau, Thibault, Thouvenot, Eric, Zephir, Hélène, Ciron, Jonhatan, Collongues, Nicolas, Kerschen, Philippe, Cohen, Mikael, Gueguen, Antoine, Mathey, Guillaume, Carra, Clarisse, Bernady, Patricia, Faucheux, Jean Marc, Planque, Evelyne, Donze, Cecile, Ruet, Aurélie, Mouzawakh, Catherine, and Pittion, Sophie
- Published
- 2017
- Full Text
- View/download PDF
33. The long‐term outcome of MOGAD: An observational national cohort study of 61 patients.
- Author
-
Deschamps, Romain, Pique, Julie, Ayrignac, Xavier, Collongues, Nicolas, Audoin, Bertrand, Zéphir, Hélène, Ciron, Jonathan, Cohen, Mikael, Aboab, Jennifer, Mathey, Guillaume, Derache, Nathalie, Laplaud, David, Thouvenot, Eric, Bourre, Bertrand, Ruet, Aurélie, Durand‐Dubief, Françoise, Touitou, Valérie, Vignal‐Clermont, Catherine, Papeix, Caroline, and Gout, Olivier
- Subjects
MYELIN oligodendrocyte glycoprotein ,OPTIC neuritis ,DISEASE relapse ,COHORT analysis ,URINARY catheterization - Abstract
Background and objective: The prognosis in myelin oligodendrocyte glycoprotein (MOG) antibody‐associated disease (MOGAD) is a matter of debate. Our aim was to assess the long‐term outcomes of patients with MOGAD. Methods: We retrospectively analysed the clinical and paraclinical data of patients from the French nationwide observatory study NOMADMUS who tested positive for MOG antibodies (MOG‐IgG) and who had clinical follow‐up of at least 8 years from their first episode. Results: Sixty‐one patients (median [range] age at onset 27 [3–69] years), with a median (mean; range) follow‐up of 177 (212.8; 98–657) months, were included. Among 58 patients with a relapsing course, 26.3% relapsed in the first year after onset. Of the 61 patients, 90.2% experienced at least one episode of optic neuritis. At last visit, the median (mean; range) Expanded Disability Status Scale (EDSS) score was 1 (2.12; 0–7.5), 12.5% had an EDSS score ≥6 and 37.5% had an EDSS score ≥3. Of 51 patients with final visual acuity (VA) data available, 15.7% had VA ≤0.1 in at least one eye and 25.5% had VA ≤0.5 in at least one eye. Bilateral blindness (VA ≤0.1) was present in 5.9% of patients. Finally, 12.5% of patients presented bladder dysfunction requiring long‐term urinary catheterization. No factor associated significantly with a final EDSS score ≥3 or with final VA ≤0.1 was found. Conclusion: Overall long‐term favourable outcomes were achieved in a majority of our patients, but severe impairment, in particular visual damage, was not uncommon. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
34. Détection des auto-anticorps antithyroïdiens dans le LCR par technique d'immunofluorométrie (FEIA) : application au diagnostic biologique de l'encéphalopathie d'Hashimoto.
- Author
-
Serrier, Julien, Branger, Pierre, Gondolf, Clémentine, Khoy, Kathy, Derache, Nathalie, Le Mauff, Brigitte, Comby, Elisabeth, and Mariotte, Delphine
- Published
- 2021
- Full Text
- View/download PDF
35. Frequency and characteristics of short versus longitudinally extensive myelitis in adults with MOG antibodies: A retrospective multicentric study.
- Author
-
Ciron, Jonathan, Cobo-Calvo, Alvaro, Audoin, Bertrand, Bourre, Bertrand, Brassat, David, Cohen, Mikael, Collongues, Nicolas, Deschamps, Romain, Durand-Dubief, Françoise, Laplaud, David, Maillart, Elisabeth, Papeix, Caroline, Zephir, Hélène, Bereau, Matthieu, Brochet, Bruno, Carra-Dallière, Clarisse, Derache, Nathalie, Gagou-Scherer, Clarisse, Henry, Carole, and Kerschen, Philippe
- Subjects
MYELITIS ,MYELIN oligodendrocyte glycoprotein ,NEUROMYELITIS optica ,TRANSVERSE myelitis ,DISABILITIES ,IMMUNOGLOBULINS - Abstract
Objectives: We aim to (1) determine the frequency and distinctive features of short myelitis (SM) and longitudinally extensive transverse myelitis (LETM) in a cohort of adults with myelin oligodendrocyte glycoprotein (MOG)-antibody (Ab)-associated myelitis and (2) determine baseline prognostic factors among MOG-Ab-positive patients whose disease started with myelitis. Material and Methods: We retrospectively analyzed clinical and paraclinical variables from a multicentric French cohort of adults with MOG-Ab-associated myelitis. At last follow-up, patients were classified into two groups according to the severity of the Expanded Disability Status Scale (EDSS) as ⩽2.5 or ⩾3.0. Results: Seventy-three patients with at least one episode of myelitis over disease course were included; among them, 28 (38.4%) presented with SM at the time of the first myelitis. Motor and sphincter involvement was less frequently observed in SM (51.9% and 48.2%, respectively) than in LETM patients (83.3% and 78.6%, respectively), p = 0.007 and p = 0.017; 61% of LETM patients displayed brain lesions compared to 28.6% in the SM group, p = 0.008, and the thoracic segment was more frequently involved in the LETM (82.2%) than in the SM group (39.3%), p < 0.001. EDSS at last follow-up was higher in LETM (median 3.0 (interquartile range: 2.0–4.0)) compared to SM patients (2.0, (1.0–3.0)), p = 0.042. Finally, a higher EDSS at onset was identified as the only independent risk factor for EDSS ⩾3.0 (odds ratio, 1.40, 95% confidence interval (CI): 1.01–1.95, p = 0.046). Conclusion: SM in MOG-Ab-associated disease is not rare. The severity at onset was the only independent factor related to the final prognosis in MOG-Ab-associated myelitis. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
36. Outcome and risk of recurrence in a large cohort of idiopathic longitudinally extensive transverse myelitis without AQP4/MOG antibodies.
- Author
-
Maillart, Elisabeth, Durand-Dubief, Françoise, Louapre, Céline, Audoin, Bertrand, Bourre, Bertrand, Derache, Nathalie, Ciron, Jonathan, Collongues, Nicolas, de Sèze, Jérome, Cohen, Mikael, Lebrun-Frenay, Christine, Hadhoum, Nawel, Zéphir, Hélène, Deschamps, Romain, Carra-Dallière, Clarisse, Labauge, Pierre, Kerschen, Philippe, Montcuquet, Alexis, Wiertlewski, Sandrine, and Laplaud, David
- Subjects
NEUROMYELITIS optica ,TRANSVERSE myelitis ,MYELIN oligodendrocyte glycoprotein ,IMMUNOGLOBULINS ,THERAPEUTIC use of immunoglobulins ,AUTOANTIBODIES ,CONVALESCENCE ,PROGNOSIS ,DISEASE relapse ,MEMBRANE glycoproteins ,MEMBRANE proteins ,PLASMAPHERESIS ,IMMUNOSUPPRESSIVE agents ,LONGITUDINAL method - Abstract
Background: Longitudinally extensive transverse myelitis (LETM) is classically related to aquaporin (AQP4)-antibodies (Ab) neuromyelitis optica spectrum disorders (NMOSD) or more recently to myelin oligodendrocyte glycoprotein (MOG)-Ab associated disease. However, some patients remain negative for any diagnosis, despite a large work-up including AQP4-Ab and MOG-Ab. Data about natural history, disability outcome, and treatment are limited in this group of patients. We aimed to (1) describe clinical, biological, and radiological features of double seronegative LETM patients; (2) assess the clinical course and identify prognostic factors; and (3) assess the risk of recurrence, according to maintenance immunosuppressive therapy.Methods: Retrospective evaluation of patients with a first episode of LETM, tested negative for AQP-Ab and MOG-Ab, from the French nationwide observatory study NOMADMUS.Results: Fifty-three patients (median age 38 years (range 16-80)) with double seronegative LETM were included. Median nadir EDSS at onset was 6.0 (1-8.5), associated to a median EDSS at last follow-up of 4.0 (0-8). Recurrence was observed in 24.5% of patients in the 18 following months, with a median time to first relapse of 5.7 months. The risk of recurrence was lower in the group of patients treated early with an immunosuppressive drug (2/22, 9%), in comparison with untreated patients (10/31, 32%).Conclusions: A first episode of a double seronegative LETM is associated to a severe outcome and a high rate of relapse in the following 18 months, suggesting that an early immunosuppressive treatment may be beneficial in that condition. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
37. Progressive Multifocal Leukoencephalopathy Incidence and Risk Stratification Among Natalizumab Users in France.
- Author
-
Vukusic, Sandra, Rollot, Fabien, Casey, Romain, Pique, Julie, Marignier, Romain, Mathey, Guillaume, Edan, Gilles, Brassat, David, Ruet, Aurélie, De Sèze, Jérôme, Maillart, Elisabeth, Zéphir, Hélène, Labauge, Pierre, Derache, Nathalie, Lebrun-Frenay, Christine, Moreau, Thibault, Wiertlewski, Sandrine, Berger, Eric, Moisset, Xavier, and Rico-Lamy, Audrey
- Published
- 2020
- Full Text
- View/download PDF
38. TeleSEP: development of platform to regional tele-expertise in multiple sclerosis
- Author
-
Derache, Nathalie, primary, LEROUX, Clément, primary, and Defer, Gilles, primary
- Published
- 2018
- Full Text
- View/download PDF
39. Quality of life and SR-fampridine in multiple sclerosis patients
- Author
-
Derache, Nathalie, primary, Defer, Gilles, primary, and Chevanne, Damien, primary
- Published
- 2018
- Full Text
- View/download PDF
40. Relapses during high doses of biotin in progressive multiple sclerosis: A case series (P5.348)
- Author
-
Branger, Pierre, primary, Derache, Nathalie, additional, Kassis, Nizam, additional, Maillart, Elisabeth, additional, Assouad, Rana, additional, and Defer, Gilles, additional
- Published
- 2018
- Full Text
- View/download PDF
41. Comparing Efficacy between Natalizumab and Fingolimod: Radiological Findings from BEST-MS Study (P1.352)
- Author
-
Cohen, Mikael, primary, Bucciarelli, Florence, additional, Ciron, Jonathan, additional, pignolet, beatrice, additional, Laplaud, David, additional, Wiertlewski, Sandrine, additional, Michel, Laure, additional, Brochet, Bruno, additional, Ruet, Aurelie, additional, Defer, Gilles, additional, Derache, Nathalie, additional, Vermersch, Patrick, additional, Zephir, Helene, additional, Debouverie, Marc, additional, Mathey, Guillaume, additional, Berger, Eric, additional, Labauge, Pierre, additional, De Seze, Jerome, additional, Mondot, Lydiane, additional, Ranc, Caroline, additional, Brassat, David, additional, and Frenay, Christine Lebrun, additional
- Published
- 2018
- Full Text
- View/download PDF
42. A one year follow up about two cases of optic neuritis under golimumab therapy (anti-TNFa) for ankylosing spondylitis revealing demyelinating disorders and multiple sclerosis
- Author
-
Maucorps, Christophe, primary, Branger, Pierre, additional, Derache, Nathalie, additional, Chawadronow, Vassili, additional, Coquerel, Antoine, additional, Defer, Gilles, additional, and Fedrizzi, Sophie, additional
- Published
- 2018
- Full Text
- View/download PDF
43. Efficacy and safety of alemtuzumab in 113 patients with active relapsing-remitting MS: one-year follow-up in France (P5.347)
- Author
-
Ayrignac, Xavier, primary, Collongues, Nicolas, additional, De Seze, Jerome, additional, Vermersch, Patrick, additional, Biotti, Damien, additional, BRASSAT, DAVID, additional, Vukusic, Sandra, additional, Durand-Dubief, Françoise, additional, Edan, Gilles, additional, Lepage, Emmanuelle, additional, Deburghgraeve, Veronique, additional, Maillart, Elisabeth, additional, Papeix, Caroline, additional, Alla, Philippe, additional, Berger, Eric, additional, Bourre, Bertrand, additional, Casez, Olivier, additional, Pittion, Sophie, additional, Debouverie, Marc, additional, Theaudin, Marie, additional, Derache, Nathalie, additional, Defer, Gilles, additional, Gout, Olivier, additional, Deschamps, Romain, additional, Tourbah, Ayman, additional, Zagnoli, Fabien, additional, Ruet, Aurelie, additional, Ouallet, Jean, additional, Brochet, Bruno, additional, Manchon, Eric, additional, Moreau, Thibault, additional, Fromont, Agnes, additional, Clavelou, Pierre, additional, Guennoc, Anne Marie, additional, Camdessanche, Jean-Phillippe, additional, Carpentier, Antoine, additional, Coman, Irene Antoanela, additional, Audoin, Bertrand, additional, Pelletier, Jean, additional, Magy, Laurent, additional, Ciron, Jonathan, additional, Wiertlevski, Sandrine, additional, Laplaud, David, additional, De Broucker, Thomas, additional, Frenay, Christine Lebrun, additional, Cohen, Mikael, additional, and Labauge, Pierre, additional
- Published
- 2017
- Full Text
- View/download PDF
44. Cerebral regions involved in executive dysfunctions in Multiple Sclerosis (P4.350)
- Author
-
Bachoumas, Panagiotis, primary, Branger, Pierre, additional, Harand, Caroline, additional, Defer, Gilles, additional, and Derache, Nathalie, additional
- Published
- 2017
- Full Text
- View/download PDF
45. Télé-SEP : mise en place d’une plate-forme de télé expertise pour la prise en charge de la sclérose en plaques au sein de la Normandie occidentale
- Author
-
Derache, Nathalie, primary, Seguin, François, additional, Hauchard, Karine, additional, and Defer, Gilles, additional
- Published
- 2017
- Full Text
- View/download PDF
46. CD62L test at 2 years of natalizumab predicts progressive multifocal leukoencephalopathy
- Author
-
Pignolet, Béatrice, primary, Schwab, Nicholas, additional, Schneider-Hohendorf, Tilman, additional, Bucciarelli, Florence, additional, Biotti, Damien, additional, Averseng-Peaureaux, Delphine, additional, Outteryck, Olivier, additional, Ongagna, Jean-Claude, additional, de Sèze, Jérôme, additional, Brochet, Bruno, additional, Ouallet, Jean-Christophe, additional, Debouverie, Marc, additional, Pittion, Sophie, additional, Defer, Gilles, additional, Derache, Nathalie, additional, Hautecoeur, Patrick, additional, Tourbah, Ayman, additional, Labauge, Pierre, additional, Castelnovo, Giovanni, additional, Clavelou, Pierre, additional, Berger, Eric, additional, Pelletier, Jean, additional, Rico, Audrey, additional, Zéphir, Hélène, additional, Laplaud, David, additional, Wiertlewski, Sandrine, additional, Camu, William, additional, Thouvenot, Eric, additional, Casez, Olivier, additional, Moreau, Thibault, additional, Fromont, Agnès, additional, Vukusic, Sandra, additional, Papeix, Caroline, additional, Vermersch, Patrick, additional, Comabella, Manuel, additional, Lebrun-Frenay, Christine, additional, Wiendl, Heinz, additional, and Brassat, David, additional
- Published
- 2016
- Full Text
- View/download PDF
47. Is it worth to report the presence of a single and additional band in the cerebrospinal fluid detected by isoelectrofocusing?
- Author
-
Lefèvre, Camille, additional, Derache, Nathalie, additional, Grandhomme, Frédérique, additional, Fradin, Sabine, additional, and Allouche, Stéphane, additional
- Published
- 2016
- Full Text
- View/download PDF
48. Cutaneous and Mixed Nerve Silent Period Recordings in Symptomatic Paroxysmal Kinesigenic Dyskinesia
- Author
-
Cogez, Julien, primary, Etard, Olivier, additional, Derache, Nathalie, additional, and Defer, Gilles, additional
- Published
- 2016
- Full Text
- View/download PDF
49. Une parésie ataxique révélant une encéphalopathie de Hashimoto avec euthyroïdie
- Author
-
Fournier, Maxime, primary, Branger, Pierre, additional, Jaillon-Rivière, Valérie, additional, Derache, Nathalie, additional, and Defer, Gilles, additional
- Published
- 2016
- Full Text
- View/download PDF
50. Cancer Risk associated with Disease-Modifying Drugs in Multiple Sclerosis: a French Registry-based Study (P1.102)
- Author
-
Lefilliatre, Mathilde, primary, Derache, Nathalie, additional, Guillaume, Elodie, additional, Droulon, Karine, additional, Launoy, Guy, additional, and Defer, Gilles, additional
- Published
- 2015
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.